Low‐dose‐rate brachytherapy for prostate cancer: A 15‐year experience in Japan-Reference-Cited by-同舟云学术

Low‐dose‐rate brachytherapy for prostate cancer: A 15‐year experience in Japan

Published:2019-09-24 Issue:1 Volume:27 Page:17-23
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Tanaka Nobumichi¹,Asakawa Isao²,Hasegawa Masatoshi²,Fujimoto Kiyohide¹

Affiliation:

1. Department of Urology Nara Medical University Kashihara Nara Japan

2. Department of Radiation Oncology Nara Medical University Kashihara Nara Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14098

Reference53 articles.

1. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy

2. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

3. Retropubic Implantation of Iodine 125 in the Treatment of Prostatic Cancer

4. Transperineal 125 Iodine Seed Implantation in Prostatic Cancer Guided by Transrectal Ultrasonography

5. Transperineal percutaneous iodine‐125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance;Blasko JC;Endocurie Hypertherm. Oncol.,1987

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of androgen‐deprivation therapy for intermediate‐ and high‐risk prostate cancer treated with high‐dose radiotherapy: A literature review;International Journal of Urology;2024-07-17

2. Identification of a novel signature based on M6a modification regulators related LncRNA for stratification of the prognosis of prostate cancer;Environmental Toxicology;2023-12-29

3. Clinical Efficacy and Openness to New Challenges of Low Dose Rate Brachytherapy for Prostate Cancer;Current Oncology;2023-11-08

4. Precision low-dose brachytherapy of prostate cancer under PSMA-receptor molecular visualization;Digital Diagnostics;2023-09-26

5. BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer;Cancers;2023-08-11